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ABSTRACT
The epigenetic code of DNA methylation is inter-
preted chiefly by methyl cytosine binding domain
(MBD) proteins which in turn recruit multiprotein
co-repressor complexes. We previously isolated
one such complex, MBD2-NuRD, from primary
erythroid cells and have shown it contributes to
embryonic/fetal b-type globin gene silencing during
development. This complex has been implicated in
silencing tumor suppressor genes in a variety of
human tumor cell types. Here we present structural
details of chicken MBD2 bound to a methylated DNA
sequence from the q-globin promoter to which it
binds in vivo and mediates developmental transcrip-
tional silencing in normal erythroid cells. While
previous studies have failed to show sequence spe-
cificity for MBD2 outside of the symmetric mCpG,
we find that this domain binds in a single orientation
on the q-globin target DNA sequence. Further, we
show that the orientation and affinity depends on
guanine immediately following the mCpG dinucleo-
tide. Dynamic analyses show that DNA binding
stabilizes the central b-sheet, while the N- and
C-terminal regions of the protein maintain mobility.
Taken together, these data lead to a model in which
DNA binding stabilizes the MBD2 structure and that
binding orientation and affinity is influenced by
the DNA sequence surrounding the central mCpG.
INTRODUCTION
DNA methylation has been the focus of extensive research
for the past several decades. This epigenetic modiﬁcation
involves the enzymatic addition of methyl groups at the
C5 position of both symmetrically related cytosine bases
in a CG dinucleotide sequence (CpG). Areas of increased
CpG content (CpG islands) are often associated with gene
promoters and when methylated are bound by regulatory
complexes that downregulate transcription. Only a subset
of CpG islands is methylated in adult tissues, which
silence expression of the associated gene in a tissue-speciﬁc
manner (1,2). Carcinogenesis has been associated with
aberrant global DNA hypomethylation and hyper-
methylation of CpG islands associated with tumor sup-
pressor genes (3–5).
The majority of methyl cytosine binding proteins spe-
ciﬁcally recognize the methylated CpG sequence through
an  60 amino acid methyl cytosine binding domain
(MBD). There are ﬁve members of the MBD family
in mammals: MeCP2, the ﬁrst to be identiﬁed (6) and
MBD1 through MBD4 (7). Outside of the methyl
binding domain itself, the amino acid sequence of each
protein is unique (with the exception of a high level of
homology between MBD2 and MBD3). The regulatory
complexes recruited and the promoter regions occupied
by each appear to be at least partially non-overlapping
and unique (8). Genetic knockouts of each MBD protein
demonstrate unique phenotypes suggesting distinct func-
tional roles (9). For example, mutations of MeCP2, many
of which are within the MBD, are associated with Rett
syndrome, a severe developmental neurological disorder
(10) and MBD2 regulatory complexes have been
implicated in silencing a small group of genes in normal
tissues including chicken and human globin genes (11–14),
the mouse IL-4 gene (15,16) and genes in the gut of the
developing mouse (15), as well as a large number of aber-
rantly methylated tumor suppressor genes in cancers such
as GSTP1 (5,17–19), p14/p16 (20), DAPK1 (21) and
KLK10 (22).
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DNA methylation and silencing of the estrogen regulated
pS2 gene. They showed that MBD2 down-regulated the
expression of pS2 when the TATA box region was
methylated and that knockdown of MBD2 restored
estrogen-dependent expression even though the DNA
remained methylated. Therefore, other MBD proteins
could not functionally substitute for MBD2 to silence
expression of pS2. These results underscore the open
question of how different MBD proteins selectively
silence different methylated promoters.
In addressing why different MBD proteins silence
distinct subsets of methylated promoters, studies have
demonstrated that MeCP2 prefers A/T sequences
adjacent to the mCpG (24) and that MBD1 preferentially
binds TmCpGCA and TGmCpGCA sequences (25). In
contrast, sequence speciﬁcity for bases outside of the
mCpG has not been previously identiﬁed for MBD2.
This latter observation raises the question of why MBD2
does not substitute for genes regulated by MBD1 and
MeCP2. One hypothesis is that the regulatory complexes
recruited by MBD2, which contain other DNA binding
domains, contribute to promoter selectivity. For
example, the MIZF protein binds to MBD2 and recog-
nizes a speciﬁc DNA sequence, which could confer
sequence speciﬁcity to the promoter targeted by MBD2.
(26,27) Alternatively, the methyl binding domain itself
could dictate which promoters are silenced. In support
of the latter, Fraga et al. (28) demonstrated variable
binding afﬁnities between isolated MBD proteins that
depends on the CpG density of the different promoters
studied.
The structures of MBD1 (29) and MeCP2 (30) methyl
binding domains bound to methylated DNA have
been solved by nuclear magnetic resonance (NMR)
spectroscopy and X-ray crystallography, respectively.
These structures have shown that the MBD selectively
binds methylated DNA through conserved arginine and
tyrosine residues that make base-speciﬁc interactions with
the mCpG sequence. The crystal structure of MeCP2
reveals that two arginine residues hydrogen bond with
the symmetrically related guanine bases of the mCpG
while a tyrosine residue makes water mediated hydrogen
bonds to the methyl group of a methylated cytosine (30).
This tyrosine has been directly implicated in the binding
selectivity for methylated DNA by mutagenesis studies
(28). Nonetheless, these studies have not provided clear
structural evidence to explain sequence speciﬁcity for
bases outside of the central mCpG.
Ginder and colleagues (11) previously identiﬁed a direct
gene promoter target for MBD2 that contributes to
silencing of the  -globin gene during normal avian eryth-
roid development. These results gave us an opportunity to
study the structural details of MBD2 bound to a bona ﬁde
target-methylated DNA sequence, important structural
information that was previously unavailable. Among the
methyl cytosine binding family of proteins, MBD2 is of
particular interest since: (i) MBD2 represents the most
phylogenetically ancient methyl cytosine binding protein,
found across vertebrate, invertebrate and plant species
(31–34); (ii) MBD2 shows the greatest degree of selectivity
for methylated versus unmethylated CpG sequences (28)
and (iii) MBD2 has been directly implicated in silencing
tumor suppressor genes in cancer (5,17–22) and as such
has been proposed as a therapeutic target for a wide-range
of human malignancies (35).
In the structural and dynamic studies reported here, we
show that the MBD of cMBD2 (96% identical to human
MBD2), recognizes a target-methylated DNA sequence
from the  -globin gene promoter in a similar manner to
both MeCP2 and MBD1. Structural details reveal differ-
ences that likely contribute to greater DNA afﬁnity and
selectivity for methylated DNA. Surprisingly, MBD2
binds this target DNA sequence in a single orientation,
which indicates previously unrecognized sequence speciﬁ-
city for bases outside of the symmetric mCpG. We show
that binding orientation depends largely on the base pairs
immediately ﬂanking the mCpG dinucleotide and that
reversing these base pairs largely, but not completely,
reverses the binding orientation. Furthermore, changing
the guanine that immediately follows the mCpG dinucleo-
tide reduces binding afﬁnity by an order of magnitude.
NMR relaxation studies of MBD2 that show the DNA
contacting region is well-structured and stable while
both the N- and C-terminal regions of the domain
undergo internal dynamic motions on fast and slow time
scales, respectively. Thus our studies suggest a model in
which the MBD2 methyl binding domain adopts a locally
well-formed structure upon DNA binding and that
binding is sensitive to the methylation status as well as
the base pairs immediately ﬂanking the mCpG. The
latter ﬁnding suggests a basis for preferential binding of
MBD2 to certain methylated and CpG rich promoters.
MATERIALS AND METHODS
Protein expression and puriﬁcation
Amino acid residues 2–72 from chicken MBD2 were
cloned and expressed as a fusion protein with thioredoxin
and a hexahistidine N-terminal tag using a modiﬁed
pET32a (Novagen) vector previously described (36).
After afﬁnity puriﬁcation using a nickel sepharose
column, the thioredoxin and hexahistidine tag were
removed by cleavage with thrombin. The protein was
further puriﬁed with sequential chromatographic isolation
over (i) benzamidine sepharose (GEHealthcare), (ii)
MonoS 10/100 GL (GEHeathcare) and (iii) Superdex 75
26/60 columns. The resulting MBD was >95% pure as
estimated by SDS–PAGE analysis. Uniform double
(
13C,
15N) and triple (
13C,
15N,
2H) labeled protein
samples were generated by standard techniques.
Sample preparation
Ten base complementary oligonucleotides with a central-
methylated cytosine were purchased (Integrated DNA
Technologies) and further puriﬁed over a MonoQ
(GE Healthcare) ion exchange column before and after
annealing. The DNA sequence was derived from the
 -globin promoter known to be a native target sequence
for MBD2 (GGAT(mC)GGCTC) (11). Puriﬁed MBD2
protein was combined with 10% excess double stranded
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6.5, 1mM dithiothreitol, 10%
2H2O and 0.02% sodium
azide and concentrated to  1mM.
For paramagnetic resonance enhancement measure-
ments, EDTA-conjugated thymidine-modiﬁed oligo-
nucleotides were purchased (Midland Certiﬁed Reagent
Company, Inc). The modiﬁed thymidine was incorporated
as (i) an additional base pair between positions 3 and 4
with EDTA–thymidine in the reverse strand and (ii) at
base pair position 9. Puriﬁed EDTA conjugated DNA
was ﬁrst stripped of any divalent cations by adding
5mM EDTA to the sample and then washed with
10mM MES pH 6.5, 500mM NaCl. Excess CaCl2 or
MnCl2 were added and the DNA extensively washed by
serial dilution and spin concentration with ﬁrst a high salt
buffer (10mM MES pH 6.5, 500mM NaCl) then low
salt NMR buffer (10mM MES pH 6.5). Then,
2H
13C
15N-cMBD2 was added to a slight excess of
EDTA conjugated DNA and the sample concentrated to
 500mM.
NMR data collection
Standard NMR experiments for resonance assignments,
distance and torsional angle restraints were measured on
a Varian 500MHz Unity+ and Bruker Avance III
TM
700MHz NMR spectrometers at 25 C. Residual dipolar
couplings were measured by adding  12mg/ml of pf1
bacteriophage to triple labeled MBD2:DNA samples and
1DNH,
1DNC0,
1DHNC0 and
1DCaC0 couplings determined
using standard inphase antiphase (IPAP)- and transverse
relaxation optimized NMR spectroscopy (TROSY)-based
experiments for both isotropic and partially aligned
samples.
Paramagnetic relaxation enhancement (PRE) measure-
ments were carried out as described by Iwahara et al.
(37,38) and Iwahara and Clore (39).
1H-
15N resonance
peak intensities were measured at four
1HN T1 (100, 300,
500 and 900ms) inversion recovery delays and two
1HN T2
(0 and 24ms) relaxation delays for cMBD2 bound to Ca
2+
and Mn
2+ saturated EDTA-conjugated DNA. Relaxation
rates were derived from ﬁtting the intensities to an inver-
sion recovery model (R1) or calculated from the ratio of
the intensities (R2) [Equations (20) and (21), Iwahara et al.
(38)] and
1HN-1 and
1HN-2 calculated as the difference
in rates between Mn
2+ and Ca
2+ saturated samples. The
1HN-1 /
1HN-2 ratio was used to estimate tc
app
[Equation (16), Iwahara et al. (38)] which was further
optimized during simulated annealing (38).
Structure calculation
The structure of the complex was calculated by simulated
annealing using the Xplor-NIH software package (40).
The minimized target function included the experimental
NMR restraints (nuclear Overhauser effect (NOE)-
derived interproton distances, torsion angles, residual
dipolar couplings and paramagnetic relaxation enhance-
ment), a quartic van der Waals repulsion term for the
non-bonded contacts (41), a torsion angle data base po-
tential of mean force (42) and a radius of gyration re-
straint to ensure optimal packing (43). Backbone torsion
angle restraints were based on chemical shifts as
determined from TALOS (44,45) and a limited number
of sidechain torsion angle restraints were derived from
measured
3JN-Cg and
3JCO-Cg coupling constants. a-Helix
and b-sheet hydrogen bond distance and angle restraints
were incorporated based on the backbone torsion angle
and characteristic NOE crosspeak patterns.
DNA assignments and NOE restraints were determined
by double ﬁltered (
13C,
15N) homonuclear NOE experi-
ments collected at 4 C, 10 C and 25 C. Importantly,
assignments of the key 5-methylcytosine H5 protons
were conﬁrmed by (i) the presence of strong NOEs
between Thy104 H6 and both Thy104 H5 and mCyt105
H5 and (ii) comparison to the double ﬁltered spectrum
of a complex with Thy104Uri-modiﬁed methylated
DNA. In addition to the NOE restraints, hydrogen
bond distance and planarity restraints as well as B-form
DNA backbone torsion angle restraints were incorporated
into structure calculations. Furthermore, PRE restraints
were incorporated using a PRE target function and a
PRE Q-factor was calculated as described by Iwahara
et al. (38). A hybrid DNA molecule incorporating an
ensemble of three alternative EDTA conformations for
each EDTA-conjugated thymidine was used in the
simulated annealing calculations.
Initial simulated annealing calculations did not incorp-
orate any intermolecular (protein:DNA) hydrogen bond
restraints. Given that both R24 and R46 sidechain He
showed strong NOE cross correlations with the mCyt105
and mCyt115 methyl protons, respectively, and that initial
calculations consistently placed these two sidechains in
close proximity to Gua106 and Gua116 bases, hydrogen
bond distance and angular restraints were incorporated
between R24/R26 NH2 and Gua106/Gua116 O6 and N7
in the ﬁnal simulated annealing calculations.
PRE and MBD orientation
In order to test for evidence of the alternative, sym-
metrically related binding orientation, an ensemble of
10 identical MBD bound to the methylated DNA were
generated and identiﬁed by 10 different segment ids
within XPLOR_NIH (40). The CpG bases from one
DNA strand were aligned to the CpG bases on the
opposite strand to generate the symmetrically rotated con-
formation of MBD. The PRE Q% was calculated with the
experimental PRE data (EDTA–thymidine between base
pairs 3 and 4) for this ensemble with 1–10 of the members
rotated to the symmetrically related orientation. This
same procedure was applied to PRE data collected with
wild-type DNA (GGAT(mC)GGCTC) and with an
inverted central 4bp (GGAC(mC)GACTC).
Binding afﬁnity
Wild-type and mutant 10bp oligonucleotides (30-
biotinylated on the forward strand) were purchased
(Integrated DNA Technologies), annealed and further
puriﬁed by ion exchange chromatography on a MonoQ
column (GE Healthcare). Wild-type and mutant MBD2
methyl-binding domain were expressed as previously and
puriﬁed by nickel sepharose and size exclusion
Nucleic Acids Research, 2011,Vol.39, No. 15 6743chromatography (10mM HEPES, 50mM NaCl, 3mM
MgCl2, 0.1mM EDTA, 1mM DTT, pH 7.4). The
puriﬁed DNA was bound to a Sensor SA chip on a
Biacore T100 (GE Healthcare) (10ng/ul DNA, 10ul/min
ﬂow rate, 100s) until a ﬁnal relative response of  120U.
Kinetic and steady state binding analysis was carried out
for varying concentrations of MBD2 proteins at a ﬂow
rate of 30 ul/min (10mM HEPES, 50mM NaCl, 3mM
MgCl2, 0.1mM EDTA, 1mM DTT, 0.05% polysorbate
20, pH 7.4). The data were ﬁt by steady state analysis
using the manufacturer’s software. At least one con-
centration of MBD2 was repeated in triplicate to
determine the analytical uncertainty of the steady state
response.
15N relaxation measurements
15N-R1,R 1r and heteronuclear NOEs were measured
using standard pulse sequences on a single deuterated
sample at 500MHz. The crosspeak intensities were ﬁt
using scripts accompanying the NMRPipe software (46).
A spin-lock ﬁeld strength of 1.5kHz was used for R1r
measurements, which were converted to R2 based on res-
onance offset and the observed R1. Data were analyzed
based on the extended model free formalism (47–49) using
the Modelfree4 software and following the protocol
described by Palmer and colleagues (50). This formalism
incorporates from one to three motional parameters for
each residue, choosing from an order parameter
(S
2=S f
2Ss
2) for both fast (Sf) and slow time scales (Ss),
an internal time scale parameter (te) representing either
a fast (tf) or slow (ts) motions and a chemical exchange
(Rex) term that incorporates pseudo-ﬁrst-order exchange
processes. The rotational correlation time (tc) estimated
from the trimmed R1/R2 ratio was used to determine the
most appropriate model of internal motion for each
residue [(i) S
2; (ii) S
2, te=tf; (iii) S
2,Rex; (iv) S
2, te=tf,
Rex and (v) Sf
2,S
2, te=ts] before ﬁtting the rotational
correlation time and internal motion parameters
globally. The appropriate model for each residue is
selected based on the sum-squared error (i) in the ﬁt as
compared to a critical value of a simulated i distribution
and an F-statistic as described (50).
RESULTS
Solution structure of cMBD2 bound to methylated DNA
We determined the solution structure of the methyl
binding domain from cMBD2 (residues 2–71) bound to
a 10bp fragment from the  -globin promoter containing
a centrally located methylated CpG sequence using multi-
dimensional NMR spectroscopy. Structures were
determined based on 783 (20 intermolecular) NOE-
derived distance constraints, 202 residual dipolar
coupling constraints, 102 protein backbone torsion angle
constraints and 136 B-form DNA torsion angle con-
straints (Table 1). In addition, EDTA conjugated thymi-
dine was incorporated in one of the two different positions
in the DNA and saturated with Mn
2+ (or Ca
2+ as a refer-
ence), as described by Iwahara et al. (38). Paramagnetic
enhanced relaxation rates were measured for 73 backbone
amide hydrogens (46 for EDTA–Thy119 and 27 for
EDTA–Thy109) and incorporated into the structure
calculations as described in the ‘Materials and Methods’
section (38). These data provide an independent measure
of the relative orientation between protein and DNA and
supplements the limited number of observed intermolecu-
lar NOEs.
The cMBD2–DNA complex structure is well deﬁned
with an overall root mean square deviation (RMSD) for
all heavy atoms of 1.1±0.1 A ˚ 2 and for backbone atoms
Table 1. NMR and reﬁnement statistics
Constraints and Statistics Protein Nucleic
acid
NMR distance and dihedral constraints
Distance restraints
Total NOE 664 119
Intraresidue 194 72
Interresidue 470 47
Sequential (|i–j|=1) 232 32
Non-sequential (|i–j|>1) 238 15
Hydrogen bonds 16 42
Hydrogen bonds protein–nucleic acid 4
Protein–nucleic acid intermolecular 20
Total dihedral angle restraints
Protein
f 56
c 46
Nucleic acid
Backbone 114
Sugar pucker 22
RDC Q% (number of constraints)
NH 6.1±0.8 (56)
H
NC0 30.6±1.4 (49)
NC0 36.3±2.5 (49)
C0Ca 44.4±2.6 (49)
PRE Q% (number of constraints)
EDTA T119 23.9±1.8 (46)
EDTA T109 26.9±1.4 (27)
Structure statistics
Violations (mean and SD for the complex)
Distance constraints (A ˚ ) 0.026±0.004
Dihedral angle constraints ( ) 0.62±0.08
Max. dihedral angle violation ( ) 10.0
Max. distance constraint violation (A ˚ ) 0.71
Deviations from idealized geometry
Bond lengths (A ˚ ) 0.0089±0.0004
Bond angles ( ) 0.604±0.004
Impropers ( ) 0.54±0.06
Average pairwise r.m.s. deviation
a (A ˚ )
Protein
Heavy 1.1±0.2
Backbone 0.7±0.2
DNA
Heavy 1.1±0.1
Backbone 0.2±0.1
Complex
Heavy 1.1±0.1
Backbone 0.8±0.2
Ramachandran plot summary
(structured residues) (%)
Most favored regions 86.1 (91.4)
Additionally allowed regions 10.6 (8.6)
Generously allowed regions 2.0 (0.0)
Disallowed regions 1.3 (0.0)
aPairwise r.m.s. deviation was calculated among 20 reﬁned structures
for structured residues (amino acids 8–69 of MBD2 and base pairs
103–108 of DNA).
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other methyl binding domains. The cMBD2 structure
consists of a long ﬁnger-like projection formed by a
three strand b-sheet (residues 18–23, 32–38 and 43–45)
with a fairly large loop between strands 1 and 2 and a
tight turn between strands 2 and 3. Immediately following
the last b-strand, the backbone turns back to form a short
a-helix (residues 47–55). The N-terminal residue of this
a-helix, S47, forms a classic N-cap through a sidechain
hydroxyl hydrogen bond with the amide hydrogen of
Q50. Neither the N- nor C-terminal regions of the MBD
domain (residues 1–17 and 56–72) forms a regular second-
ary structure and both of these regions pack against the
b-sheet opposite the DNA binding surface of the protein.
The ﬁnger-like projection of cMBD2 extends down into
the major groove of DNA to make contact with the sym-
metrically methylated CpG sequence. Three residues make
base-speciﬁc contacts with the methylated CpG: R24, Y36
and R46. The two arginines form hydrogen bonds with the
two symmetrically opposed guanine bases (Gua106 and
Gua116), which permits the aliphatic side chains of each
arginine to pack against the neighboring methyl-cytosine
methyl groups (mCyt105 and mCyt115). The aromatic
side chain of Y36 interacts with the methyl groups of
mCyt105 and the neighboring Thy104 (Figure 1c).
D34 potentially stabilizes the conformation of R24
through a sidechain hydrogen bond and makes a direct
hydrogen bond with the hydroxyl of Y36. The positively
charged amino acids R67 and K44 form close ionic inter-
actions with the phosphate backbone from Cyt114 and
Ade103–Thy104, respectively. K32 adopts multiple
conformations in the 20 simulated annealing structures,
forming either base-speciﬁc contacts with Gua107 (in the
majority of structures) or an ionic interaction with the
backbone phosphate of Ade112.
In addition to the individual amino acid–DNA inter-
actions, the positive end of the helical dipole points
towards the negatively charged backbone phosphate of
mCyt115, contributing to binding. S47 from this helix
closely approaches the phosphate backbone of DNA
and can form a sidechain hydrogen bond with the
backbone phosphate of mCyt115 (in addition to the
N-cap hydrogen bond with the backbone amide of Q50).
Hence, the MBD spans the major groove to make
base-speciﬁc hydrogen bond and aliphatic interactions
with the central-methylated CpG, ionic, hydrogen bond
and helical dipole interactions with the phosphate
backbone on both sides of the major groove and
Figure 1. Solution structure of cMBD2 methyl binding domain bound to methylated DNA. (a) A best-ﬁt superimposition licorice diagram of protein
backbone (cyan) and DNA heavy atoms (blue) is shown for the ensemble of 20 calculated structures. (b) A stereo cartoon diagram of a representative
MBD2 (cyan) and DNA (blue/orange) is shown. (c) A detailed line diagram of the protein:DNA interface is depicted with contacting protein residues
(cyan) and mCpG DNA bases (yellow) shown as sticks. (d) A diagram depicting base-speciﬁc (solid lines) and phosphate backbone (dashed lines)
contacts between MBD2 and DNA (for simplicity, only the central 6bp are shown). Structure ﬁgures were generated with (a) VMD-XPLOR (65)
and (b, c) PyMOL (Delano Scientiﬁc, LLC).
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residues outside of the mCpG.
Comparison with other MBD proteins
The complex between cMBD2:DNA is similar to the pre-
viously reported structures of MeCP2 and MBD1 methyl
binding domains bound to methylated DNA (29,30). The
methyl binding domain from cMBD2 shares 60% identity
(74% homology) with human MBD1. The structures of
these two domains are very similar, with a backbone
RMSD of 2.2A ˚ . The secondary structures align closely
and the domains share many of the same features
discussed for MBD2. The residues that directly inter-
act with DNA are conserved between the two proteins
and make very similar interactions with the DNA.
However, MBD1 is rotated slightly and the binding
surface more closely approximates the DNA than
MBD2 (Supplementary Figure S1). This difference in
global orientation alters some of the ﬁne details and
reﬂects subtle differences in how the two proteins
bind methylated DNA. For example, the loop between
b1 and b2 of MBD1 closely approaches the DNA
such that the amide hydrogen of A26 forms a hydrogen
bond with the backbone phosphate of Gua107. The
hydroxyl of Y34 of MBD1 can form a direct hydro-
gen bond with the N4 of mCyt106, as opposed to an
interaction with the methyl group of mCyt seen for
MBD2 (potentially a water-mediated hydrogen bond as
seen for MeCP2) (30). V47 sidechain methyl groups
pack against the deoxyribose of Cyt117 and R18 of
MBD1 closely interacts with the phosphate backbone
of Thy104.
The MBD from cMBD2 shares 50% identity (56%
homology) with human MeCP2. While the b-sheet
region is very similar, with a backbone RMSD of 2.4A ˚
for alignment with cMBD2 residues 9–55, MeCP2 has
a longer a-helix incorporating an additional turn
(4 residues) and consequently an additional 5–6 residues
in the C-terminal region that packs against this same helix.
These additional residues cause the a-helix to adopt
a more oblique angle with respect to the DNA phosphate
backbone (Supplementary Figure S1). Despite these
changes, MeCP2 and cMBD2 bind the methylated CpG
sequence in a very similar manner. Both proteins contact
the central mCpG with virtually identical interactions
involving residues R24(111), R46(133) and Y36(123) in
cMBD2(MeCP2).
The most notable differences between the cMBD2 and
MeCP2 complexes involve residues outside of the mCpG
binding region. K44 of cMBD2 (A31 of MeCP2) provides
an additional ionic interaction while L28 (R114 of
MeCP2) eliminates an ionic interaction with the phos-
phate backbone of DNA. The latter change helps
explain why the loop between b-strands 1 and 2 of
cMBD2 (residues 24–31) deviates away from the DNA
relative to MeCP2. R67 replaces T158 to form a close
ionic interaction with DNA phosphate backbone. The
net result is an additional ionic interaction that is likely
to contribute to the observed higher binding afﬁnity and
possibly greater speciﬁcity for methylated DNA by
MBD2, as conﬁrmed by the reduced binding afﬁnity for
the R67M mutant (Table 2; see below).
Orientation preference for cMBD2 binding to methylated
DNA
Given the apparent lack of sequence selectivity previously
reported (24) and that the mCpG DNA sequence is pal-
indromic, we fully anticipated that cMBD2 would bind
equally in either of two symmetrically related orientations.
Surprisingly, the NOE and PRE data are most consistent
with a single orientation of cMBD2 on this DNA. Among
the 20 intermolecular protein:DNA NOEs, two particular-
ly strong orientation speciﬁc intermolecular NOE peaks
were identiﬁed between the He of R24 and R46 and the
H5 methyl hydrogens of mCyt105 and mCyt115, respect-
ively (Figure 2a). Likewise, the PRE data ﬁt well with
this orientation of cMBD2 (EDTA Thy119 PRE
Q%=23.9±1.8, see Table 1). To explore how strongly
the data favored one orientation, we reversed the orienta-
tion of cMBD2 on the DNA in silico and minimized the
conformation of the EDTA-conjugated Thy119 ensemble.
The ﬁt to PRE data for the reverse orientation was signiﬁ-
cantly worse (Q%=36.7) even though minimization
allowed the conjugated EDTA ensemble to adopt
disparate conformations.
This observation suggests that cMBD2 adopts predom-
inantly one orientation on the methylated  -globin gene
promoter sequence. However, the data do not exclude the
possibility that the complex exists as a rapidly exchanging,
albeit skewed, mixture between these two orientations.
Paramagnetic relaxation enhancement is very sensitive to
minor conformations and has been used to detect rarely
populated states (51). To explore the possibility of rapid
exchange between these two orientations, we generated
10 alternative copies of the cMBD2 domain in silico and
evaluated whether the experimental PRE data ﬁt better
when averaged over an ensemble of the two possible
orientations. As can be seen in Figure 2b, the data ﬁt
best (lowest PRE Q%) when all 10 members of the
ensemble adopt the same orientation as that determined
initially. Therefore, these experimental results are most
consistent with a single orientation of cMBD2 on this
methylated target sequence.
The propensity to bind in a single orientation implies
unanticipated sequence selectivity for bases surrounding
the mCpG. Since (i) previous SELEX experiments failed
Table 2. Binding afﬁnity
MBD2 mCpG KD (mM)±SE Rmax  
2
WT WT 2.1±0.1 323 15.1
K32A WT 291±19 501 0.4
Y36F WT 109±3 497 0.69
R46C WT 590±71 678 1.9
R67M WT 197±17 464 8.2
K19W WT 135±17 334 17.5
WT Thy104Gua 2.2±0.1 247 2.8
WT Gua107Thy 29±2 402 10.6
WT Inverted 2.3±0.5 86 5.5
6746 Nucleic Acids Research, 2011,Vol.39, No. 15to detect selectivity of MBD2 for bases surrounding an
invariant C(mC)GG central 4bp (in contrast to the clear
preferential binding of MeCP2 to sequences containing
A/T rich stretches adjacent to the mCpG) (24) and
(ii) the majority of DNA contacts involves these central
4bp, we hypothesized that the binding orientation
depends solely on the central four base T(mC)GG
sequence. To test this hypothesis, we analyzed binding
to a modiﬁed sequence in which the central T(mC)GG
was reversed to C(mC)GA. As can be seen in Figure 2a,
strong intermolecular NOEs were identiﬁed between the
He of R24 and R46 and the methyl hydrogen of mCyt1150
and mCyt1050, respectively, which is the reverse of the
pattern seen with the wild-type sequence. The chemical
shift difference between these two methyl groups on the
DNA is much smaller than for the wild-type sequence
(0.013ppm versus 0.06ppm, respectively) and this
chemical shift difference increases at lower temperature
(0.02ppm at 10 C). Together, these observations indicate
that reversing the sequence of the central four bases has
reversed the DNA binding orientation but also raise the
possibility that binding now involves a rapidly exchanging
mixture of orientations due to the decrease in chemical
shift differences between the mCyt methyl groups and
the line-broadening seen in Figure 2a. To further
evaluate this possibility, PRE data were collected using
EDTA-conjugated Thy119 in the modiﬁed DNA
sequence. If we assume the PRE data pertain to a single
orientation, the PRE data ﬁt best to the reverse orienta-
tion of cMBD2; however, the overall best ﬁt of PRE data
occurs using a mixed ensemble of cMBD2 orientations
with the predominant orientation in the reverse direction
( 80%, Figure 2b).
Binding afﬁnity
Wild-type MBD2 binds the methylated DNA sequence
with very fast on- and off-rates and an overall KD
 2.1mM (Table 2, Figure 3a and b). Additional binding
analyses were performed with select MBD2 mutants
(K32A, Y36F, R46C, R67M, K19W), the latter three of
which are homologous to the more common missense
mutations of MeCP2 associated with Rett syndrome
(R133C, T158M, R106W). Mutations that affect direct
interaction with DNA (K32A, Y36F, R46C and R67M)
reduce binding by at least 50-fold (Table 2). The R46C
mutation in particular markedly decreases binding, afﬁrm-
ing the central role of the R46-Gua116 hydrogen bonding
interaction. The K32A mutation removes a residue that
can form a base-speciﬁc interaction with Gua107 and an
ionic interaction with the phosphate backbone. The Y36F
mutation reduces binding afﬁnity by removing a single
hydroxyl group that interacts with the methyl group of
the mCyt105 (28,52). R67M, which decreases binding
by nearly 100-fold, is homologous to one of the most
common Rett syndrome missense mutations (T157M);
however, in MBD2 the sidechain of R67 interacts with
the phosphate backbone of DNA while in MeCP2 T157
plays a role stabilizing two consecutive turns of the protein
backbone. As discussed previously, this additional ionic
interaction with DNA is likely to contribute to an
Figure 2. Orientation preference for MBD2 bound to methylated
 -globin DNA sequence. (a)3 D
15N-HSQC-NOESY slices correspond-
ing to the Ne-He of Arg24 and Arg46 of MBD2 when bound to
wild-type and inverted DNA sequences. NOE crosspeaks for
mCyt105H5 and mCyt115H5 are labeled. (b) PRE Q values are
calculated over an ensemble of MBD2 orientations for data obtained
when bound to wild-type (solid line) and inverted (dashed line) DNA
sequences. The ensemble consists of 10 copies of MBD2 with 0–10 of
these having a reversed orientation with respect to the DNA. (c)A
cartoon diagram shows the two alternative MBD2 orientations that
make up the ensemble. The orientation as solved by NMR for
wild-type DNA (cyan) and a symmetrically reversed orientation
(yellow) are depicted.
Nucleic Acids Research, 2011,Vol.39, No. 15 6747overall higher binding afﬁnity for MBD2 as compared to
MeCP2 and MBD1.
The sidechain of K19 does not directly interact with
DNA; instead the lysine sidechain forms a partially
buried interaction with the backbone of G69—linking
the ﬁrst b-strand with the C-terminus of the MBD. The
K19W mutation decreases binding afﬁnity by nearly
70-fold suggesting that destabilizing this interaction
indirectly affects DNA binding.
As discussed previously, Y36 and K32 interact with the
bases of Thy104 and Gua107, respectively, forming the
only base-speciﬁc interactions outside of the central
mCpG. To test whether these base-speciﬁc interactions
help dictate binding orientation, we determined the
afﬁnity of MBD2 for Thy104Gua and Gua107Thy sub-
stitutions. Although Thy104Gua removes a methyl
group that contacts Y36, this change does not appre-
ciably alter binding afﬁnity (Table 2 and Figure 3c).
In contrast, the Gua107Thy substitution reduced binding
afﬁnity by at least 10-fold, indicating that the
K32–Gua107 interaction strongly favors the observed
orientation of MBD2 on the wild-type DNA.
Furthermore, reversing the central four bases to
C(mC)GA did not affect the binding afﬁnity (‘inverted’
DNA in Table 2 and Figure 3c). This latter observation
is consistent with MBD2 binding in the reverse orientation
(as shown above), which preserves the K32–Gua
interaction.
Internal dynamics of cMBD2
15N relaxation and heteronuclear NOE data were
analyzed using the modiﬁed model-free formalism with
the Modelfree4 software and following the protocol
described by Palmer and colleagues (50). The overall
rotational correlation time (tc) for the ﬁnal model was
8.0ns. The overall internal order parameters
(S
2=S f
2Ss
2), internal fast or slow rotational correlation
times (te) and slow exchange terms (Rex) for each
residue are shown in Figure 4a and Supplementary
Table S1. Out of a total of 57 backbone
15N analyzed,
23 were ﬁt by model 1 (<S
2>=0.90±0.05); 7 by
model 2 (<S
2>=0.75±0.11); 12 by model 3
(<S
2>=0.84±0.07); 10 by model 4 (<S
2>=
0.76±0.11); 5 by model 5 (<S
2>=0.41±0.16). Both
the N- and C-terminal regions show evidence of internal
motions, best characterized as fast time scale internal
motions for the N-terminus (Model 5 with a large te for
residues 4–7 and 10) and a slow exchange process (Rex)
most pronounced for residues after the a-helix (residues
57–72).
The order parameters were mapped onto the solution
structure and color coded with red the most dynamic
(lowest S
2) and blue, most structured (highest S
2)
residues. As can bee seen in Figure 4b, the b-sheet and
DNA contacting regions are well structured while the
N- and C-terminal regions form a structurally dynamic
‘lid’ sitting down on this stable b-sheet platform. In fact,
part of the motivation for these measurements came from
the observation that residues from both regions (i.e. T8,
D65, R66 and T68) were broadened or completely absent
from the
15N-HSQC spectrum. These results show that
DNA contact stabilizes the b-sheet region while regions
remote from the protein:DNA interface show internal
mobility.
DISCUSSION
The methyl binding domain demonstrates a remarkable
ability to distinguish symmetrically methylated from
unmethylated CpG sequences. This domain is highly
conserved and can be found across vertebrate, inverte-
brate and plant species (32–34). In mammals, ﬁve MBD
containing proteins have been identiﬁed. The MBD2
protein has been associated with silencing of embryonic/
fetal hemoglobin expression (11–14), the mouse IL-4 gene
(15,16) and genes in the gut of the developing mouse (15)
and is frequently associated with silencing of a subset of
aberrantly methylated tumor suppressor genes in cancer
(5,17–22,35). In vitro binding studies of an MBD2 contain-
ing complex from primary chicken red cells suggested
a sequence preference for the  -globin promoter region
over the generic CpG-rich sequence CG11 (14). These
Figure 3. Binding afﬁnity of cMBD2 to methylated DNA. (a) Surface plasmon resonance analysis for varying concentrations of wild-type
cMBD2 binding to a 30-biotinylated and methylated 10bp target sequence coupled to a Sensor Chip SA on a Biacore T100 (GE Healthcare).
Steady state binding response was analyzed for varying concentrations of cMBD2 with (b) speciﬁc point mutations or (c) binding to modiﬁed DNA
sequences. The data were ﬁt using the Biacore T100 evaluation software. For comparison, the response units for each were normalized to an
Rmax=100 (Table 2).
6748 Nucleic Acids Research, 2011,Vol.39, No. 15observations raise the question of whether the methyl
binding domain itself contributes to promoter-speciﬁc
binding and functional divergence.
Binding afﬁnity and orientation preference
In these structural studies, we use a combination of PRE
and intermolecular NOEs to accurately determine the
solution structure of MBD2 bound to DNA. PRE repre-
sents an independent measure to augment limited NOE
data and allows one to investigate minor binding modes.
(37,39,53) Together, the data strongly support a model in
which cMBD2 binds almost entirely in one orientation on
the wild-type-methylated target sequence from the chicken
 -globin promoter. This orientation preference depends
primarily, but not solely, on the bases immediately
adjacent to the mCpG dinucleotide. Reversing the direc-
tion of the central four bases, which is equivalent to
simply exchanging the base pairs on either side of the
mCpG, reverses the predominant binding orientation of
cMBD2. However,  20% of the cMBD2 population
binds in the original orientation on this reverse
sequence, indicating that the sequence outside of the
central four bases inﬂuences the preferred orientation.
We determined the binding afﬁnity for wild-type and
mutated MBD2 as well as variations of the target
binding sequence to conﬁrm the importance of individual
protein–DNA interactions. Mutating residues that are
involved in direct DNA contact signiﬁcantly decreases
binding afﬁnity. Importantly, we ﬁnd that a base-speciﬁc
interaction between K32 and Gua107 contributes to
high-afﬁnity binding. This observation is consistent with
prior studies showing that lysine residues preferentially
form bidentate and complex base-speciﬁc hydrogen
bonds with guanine bases (54). Therefore, the data
Figure 4.
15N-relaxation dynamic analysis of cMBD2 bound to DNA. (a) Model free parameters (S
2, te and Rex) derived from
15N-relaxation data
are plotted against residue number. (b) A stereo cartoon diagram of the cMBD2-DNA structure is shown and colored according to generalized order
parameter from high (blue) to low (red), with proline residues (not included in the analysis) colored dark gray and residues with broadened amide
resonances (not included, but likely to undergo slow exchange motions) colored peach. Structurally equivalent residues for some of the most common
Rett syndrome missense mutations are depicted as spheres.
Nucleic Acids Research, 2011,Vol.39, No. 15 6749support a model in which the base-speciﬁc K32–Gua107
interaction increases binding afﬁnity and leads to the
observed preferred orientation on the target DNA
sequence.
Bird and colleagues (24) tested for evidence of DNA
sequence selectivity for both MBD2 and MeCP2 using
a SELEX based experiment. In those studies, sequence
preferences were identiﬁed by sequential enrichment
from a pool DNA oligonucleotides with random bases
surrounding a central 4bp C(mC)GG sequence. The
results of their SELEX experiments demonstrated that
MeCP2 preferentially binds sequences with a short run
( 4) of [A/T] base pairs while MBD2 failed to show any
sequence selectivity for residues ﬂanking the C(mC)GG
bases (24).
Our solution NMR studies of MBD2, which involve
only the MBD from MBD2, show strong evidence of
a single orientation on this methylated target DNA
sequence and a binding afﬁnity preference for the
guanine immediately following the mCpG. The wild-type
DNA sequence was derived from a known in vivo target
sequence for cMBD2 binding during normal erythroid
development (11), which suggests potential functional sig-
niﬁcance for the orientation of the MBD. One possibility
is that the MBD2 dictates the orientation of the associated
coregulatory complex. MBD2 recruits and tightly inter-
acts with the multi-protein nucleosome remodeling and
deacetylation (NuRD) complex (55,56). The NuRD
complex is one of many chromatin remodeling complexes
that alter nucleosome position and chromatin structure
to modify gene expression (57–59). One component of
NuRD, the Mi2 protein, contains a helicase-like ATPase
domain implicated in energy dependent repositioning of
nucleosomes (55). Most models of nucleosome remodeling
implicate sliding of chromatin remodeling complexes
(either step-wise or continuous) along the DNA to repos-
ition the nucleosome (60). The orientation of MBD2 on
DNA could orient the NuRD complex, which would
then direct the ﬁnal localization of the nucleosome.
In addition, we have shown a sequence preference for a
guanine residue immediately following the mCpG. To
explore whether this sequence preference could explain
MBD2 promoter selectivity, we examined the CpG
islands from several known target promoters for MBD2
(DAPK1, GSTP1 and BRCA1). We ﬁnd an overrepre-
sentation of either CGG or CGC sequences in these
CpG islands (i.e. for the DAPK1 CpG island, 62% of
CpG sequences contain a CGG on either strand while
only 16% contain CGT). However, it is unclear whether
this bias reﬂects the CG rich nature of CpG islands in
general or a feature that is selectively targeted by
MBD2. To conﬁdently assign functional signiﬁcance to
the mCpGG sequence preference of MBD2 will require
more extensive in vivo analyses of methylated target
promoters.
Hence, the orientation preference, we have detected
could contribute to MBD2 function by (i) reﬂecting an
afﬁnity preference that dictates, which promoters are pref-
erentially bound by MBD2 and/or (ii) determining the
orientation of NuRD on the DNA to direct reposition
of the nucleosome, thereby inﬂuencing which promoters
are silenced by MBD2. The former possibility might in
part explain the overlapping but distinct associations
between MBD2 versus MeCP2 and speciﬁc methylated
gene promoters.
Structural dynamics of MBD2
The results of the dynamic studies indicate that the b-sheet
region forms a stable platform interacting with DNA. In
contrast, the N- and C-terminal regions undergo internal
dynamic ﬂuctuations forming a dynamic lid that packs
against the b-sheet opposite the DNA binding surface
(Figure 3c). While not surprising that solvent-exposed
N- and C-terminal residues are more mobile, the
dynamic regions identiﬁed in MBD2 are fairly extensive
and include residues involved in hydrophobic packing
(i.e. L61 and F64). These observations, in conjunction
with marked line-broadening seen in the
15N-HSQC
spectra of free MBD2, suggest that DNA contact stabil-
izes the core structure of the MBD. While as yet no known
human disease has been associated with mutations of
MBD2, some of the more common MeCP2 missense
mutations associated with Rett syndrome are found in
the MBD. In Figure 3b, residues in cMBD2 that are the
structural equivalent of the more common MeCP2
missense mutations associated with Rett (L100, R106,
R133, S134, P152, F155 and T158 of MeCP2) are
depicted. Several of the mutations occur at the protein
DNA interface and impact binding directly (R46, S47
and R67), as demonstrated by binding afﬁnity analysis
(Table 2). Many of these mutations, however, occur at
the interface between the b-sheet and the dynamic
N- and C-terminal regions (L13, K19, L61 and F64)
indicating that these changes are likely to affect function
by further destabilizing the more dynamic regions of the
protein. We showed that the K19W mutation, which is
remote from the DNA interface, does reduce binding
afﬁnity by 70-fold. These observations are consistent
with recent work by Ghosh et al. (61), which showed
that the Rett-associated mutations led to thermal destabil-
ization and reduced DNA binding afﬁnity of MeCP2.
Hence, our data support a model in which destabilizing
the packing of the N- and C-terminal regions against the
b-sheet modiﬁes interaction with DNA and disrupts
function. Consistent with this model, the regions of
increased internal dynamics we report for cMBD2
correlate well with the B-factors reported for the crystal
structure of MeCP2-bound to methylated DNA (30).
As has been suggested for destabilizing mutations of p53
(62–64), a potential molecular therapeutic approach could
involve agents that bind and stabilize both the N- and
C-terminal regions to overcome the functional deﬁcits
caused by these missense mutations.
Summary
The solution structure of cMBD2 MBD bound to a
target-methylated sequence reveals common and unique
features of how this domain recognizes the mCpG
dinucleotide. This MBD has the highest afﬁnity and
greatest selectivity for methylated MBD proteins,
yet a sequence preference has not been previously
6750 Nucleic Acids Research, 2011,Vol.39, No. 15demonstrated. In these studies, we show that cMBD2
MBD adopts a single orientation on a methyated
 -globin promoter target sequence despite the symmetry
of the mCpG. This orientation preference indicates
sequence speciﬁcity primarily dependent on the bases
immediately ﬂanking the mCpG. Furthermore, binding
to DNA leads to a well-structured core b-sheet packing
against more dynamic N- and C-terminal regions. Both
the orientation preference and internal dynamic suggest
functional connections between DNA binding by this
domain and recruitment of the NuRD remodeling
complex in a preferential manner to speciﬁc methylated
CpG-rich promoters to silence expression of the
associated gene.
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